RAB29抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse kidney tissue, Rat kidney tissue lysates, Primary antibody: P02856(RAB29 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P02856(RAB29 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P02856(RAB29 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

RAB29. a member of the Rab GTPase family, plays a critical role in regulating intracellular membrane trafficking, particularly in endosomal compartments and the trans-Golgi network. It is implicated in maintaining organelle integrity, vesicular transport, and autophagy. Notably, RAB29 has gained attention due to its interaction with leucine-rich repeat kinase 2 (LRRK2), a protein linked to Parkinson’s disease (PD). Mutations in LRRK2 are among the most common genetic causes of familial and sporadic PD, and RAB29 is thought to modulate LRRK2’s kinase activity, influencing pathogenic signaling pathways.

Antibodies targeting RAB29 are essential tools for studying its expression, localization, and function in cellular and disease models. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate RAB29’s role in membrane dynamics, lysosomal function, and PD-related mechanisms. Studies utilizing RAB29 antibodies have revealed altered expression levels in PD patient-derived cells and animal models, supporting its relevance in disease pathology.

Validated RAB29 antibodies are characterized for specificity through knockdown/knockout controls, ensuring reliable detection across species (e.g., human, mouse). Their application aids in elucidating how RAB29-LRRK2 interactions contribute to neurodegeneration, potentially guiding therapeutic strategies targeting this pathway in PD and related disorders.